

Fig. 1 VASCULAR CELL MOLECULAR TARGETS & SIGNALING INFORMATION




Fig. 2 DETAILED SIGNALING PATHWAYS IN A VASCULAR SMOOTH MUSCLE CELL
HORMONES & TRANSMITTERS





Fig. 3

MOLECULAR SITES OF DRUG ACTION IN PREFERRED ARTHROSCOPIC SOLUTION

3/12



MOLECULAR SITES OF DRUG ACTION IN PREFERRED CARDIOVASCULAR & GENERAL VASCULAR SOLUTION - I/II


Fig. 44

HORMONES & TRANSMITTERS

5HT₂ ANTAGONIST (-)


ET_A ANTAGONIST (-)


THROMBIN ANTAGONIST (-)



MOLECULAR SITES OF DRUG ACTION IN PREFERRED CARDIOVASCULAR & GENERAL VASCULAR SOLUTION - II/II

Fig. 5






MOLECULAR SITES OF DRUG ACTION IN PREFERRED GENERAL SURGICAL WOUND SOLUTION

Fig. 7


HORMONES & TRANSMITTERS



7/12

MECHANISM OF ACTION OF NO DONOR DRUGS ON A VASCULAR SMOOTH MUSCLE CELL.

Fig. 8



9/12




Fig. 9




Fig. 10A




Fig. 10B




Fig. 11 DOSE OF I.V. AMITRIPTYLINE (mg/kg)




Fig. 12 CONCENTRATION I.A. AMITRIPTYLINE (nM)

11/12




Fig. 13




Fig. 14

12/12




Fig. 15